EU regulators back Mirati's lung cancer drug
10/11/2023 12:41
Nov 10 (Reuters) - Mirati Therapeutics MRTX.O said on
Friday that the European Union's medicines regulator has
recommended its treatment named Krazati for a type of lung
cancer.
(Reporting by Christy Santhosh; Editing by Janane Venkatraman)
((Christy.Santhosh@thomsonreuters.com;))
Recent news on Mirati Therapeutics
See all newsBrief: European Commission Approves KRAZATI As A Targeted Treatment For Non-Small Cell Lung Cancer
US FDA turns down Amgen lung cancer drug Lumakras for full approval (updated)
US FDA turns down Amgen lung cancer drug Lumakras for full approval
Brief: Mirati Stockholders Voted 'For' Proposal To Adopt Deal Between Co, Bristol-Myers Squibb
Mirati's lung cancer drug gets EU's regulatory backing (updated)